Literature DB >> 21840568

Neuropilin-2: a novel biomarker for malignant melanoma?

Erica C Rushing1, Megan J Stine, Sarah J Hahn, Sofia Shea, Mark S Eller, Alaa Naif, Sarika Khanna, William H Westra, Achim A Jungbluth, Klaus J Busam, Meera Mahalingam, Rhoda M Alani.   

Abstract

Neuropilin-2, a cell surface receptor involved in angiogenesis and axonal guidance, has recently been shown to be a critical mediator of tumor-associated lymphangiogenesis. Given that lymphangiogenesis is a major conduit of metastasis in melanomas and that blocking neuropilin-2 function in vivo is effective in inhibiting tumor cell metastasis, we sought to determine the clinical relevance of neuropilin-2 expression in cutaneous melanoma. Immunohistochemical analysis of neuropilin-2 expression was evaluated in nevomelanocytic proliferations that included a tissue microarray and histologic sections from samples of primary melanomas (n = 42; 40 for tissue microarray, 2 for histologic sections), metastatic melanomas (n = 30; 22 for tissue microarray, 8 for histologic sections), and nevi (n = 30; 5 for tissue microarray, 25 for histologic sections), as well as a panel of normal human tissues and select nonmelanocytic tumors. Staining for grading and intensity of neuropilin-2 expression was estimated semiquantitatively as follows for the former: less than 20%, 20% to 60%, and more than 60% of tissue present, and for the latter from 0 to 3, with 3 being the highest and 0 the lowest intensity. In nevomelanocytic proliferations, more than 20% staining for neuropilin-2 was noted in 36 (86%) of 42 cases of primary melanoma, in 27 (90%) of 30 cases of metastatic melanoma, and in 9 (30%) of 30 cases of nevi with differences achieving statistical significance between melanoma (primary and metastatic) and nevi (P < .0001). For staining intensity, an intensity of 2 or more was noted in 36 (86%) of 42 cases of primary melanoma, in 17 (57%) of 30 cases of metastatic melanoma and in 7 (30%) of 23 cases of nevi, with differences achieving statistical significance between melanoma (primary and metastatic) and nevi (P < .0001). In normal human tissue, consistently strong neuropilin-2 staining was noted in kidney (glomerular endothelial cells, collecting tubules, and collecting ducts), skin (epidermal keratinocytes), and testes (epithelium of the seminiferous tubules), whereas in tumoral tissue, consistently strong staining was noted only in renal cell carcinoma but not in any of the other tumors studied. More recently, using a heterotypic coculture methodology with melanoma and endothelial cells, we have demonstrated successful up-regulation of neuropilin-2 and confirmed the critical role of neuropilin-2 in melanoma-endothelial interactions. Because these coculture methods were developed to model melanoma metastasis, the significantly increased and enhanced expression of neuropilin-2 staining in primary and metastatic melanoma versus nevi in the current study suggests that it is also relevant in vivo.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840568      PMCID: PMC3246122          DOI: 10.1016/j.humpath.2011.05.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

Authors:  Jordi Graells; Antonia Vinyals; Agnes Figueras; Ana Llorens; Abelardo Moreno; Joaquim Marcoval; F Jesus Gonzalez; Angels Fabra
Journal:  J Invest Dermatol       Date:  2004-12       Impact factor: 8.551

2.  Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes.

Authors:  Soheil S Dadras; Bernhard Lange-Asschenfeldt; Paula Velasco; Lynh Nguyen; Anish Vora; Alona Muzikansky; Katharina Jahnke; Axel Hauschild; Satoshi Hirakawa; Martin C Mihm; Michael Detmar
Journal:  Mod Pathol       Date:  2005-09       Impact factor: 7.842

3.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.

Authors:  Diane R Bielenberg; Yasuhiro Hida; Akio Shimizu; Arja Kaipainen; Michael Kreuter; Caroline Choi Kim; Michael Klagsbrun
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Lymphatic vessel density is significantly increased in melanoma.

Authors:  T A Giorgadze; P J Zhang; T Pasha; P S Coogan; G Acs; D E Elder; X Xu
Journal:  J Cutan Pathol       Date:  2004-11       Impact factor: 1.587

Review 5.  Roles of neuropilins in neuronal development, angiogenesis, and cancers.

Authors:  Changyi Chen; Min Li; Hong Chai; Hui Yang; William E Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

6.  Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors.

Authors:  Klaus J Busam; Urvi Mujumdar; Amanda J Hummer; Jennifer Nobrega; William G Hawkins; Daniel G Coit; Mary S Brady
Journal:  Am J Surg Pathol       Date:  2004-11       Impact factor: 6.394

7.  Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines.

Authors:  Sylvie Lantuéjoul; Bruno Constantin; Harry Drabkin; Christian Brambilla; Joëlle Roche; Elisabeth Brambilla
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 8.  Angiogenesis and lymphangiogenesis of skin cancers.

Authors:  Soheil S Dadras; Michael Detmar
Journal:  Hematol Oncol Clin North Am       Date:  2004-10       Impact factor: 3.722

9.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Authors:  Soheil S Dadras; Thomas Paul; Jennifer Bertoncini; Lawrence F Brown; Alona Muzikansky; David G Jackson; Ulf Ellwanger; Claus Garbe; Martin C Mihm; Michael Detmar
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.

Authors:  Dennis A Faith; William B Isaacs; James D Morgan; Helen L Fedor; Jessica L Hicks; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Elizabeth A Platz; Jun Luo; Angelo M De Marzo
Journal:  Prostate       Date:  2004-11-01       Impact factor: 4.104

View more
  11 in total

1.  MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3.

Authors:  Xuguang Zheng; Michael Chopp; Yong Lu; Benjamin Buller; Feng Jiang
Journal:  Cancer Lett       Date:  2012-11-07       Impact factor: 8.679

Review 2.  Neuropilins: expression and roles in the epithelium.

Authors:  Jonathan R L Wild; Carolyn A Staton; Keith Chapple; Bernard M Corfe
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

Review 3.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

4.  Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin.

Authors:  Luke H Hoeppner; Steven Bach; Guangqi E; Ying Cao; Yan Guo; Enfeng Wang; Jianmin Wu; Mark J Cowley; David K Chang; Nicola Waddell; Sean M Grimmond; Andrew V Biankin; Roger J Daly; Xiaohui Zhang; Debabrata Mukhopadhyay
Journal:  Cancer Res       Date:  2013-05-20       Impact factor: 12.701

Review 5.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 6.  Neuropilins in the Context of Tumor Vasculature.

Authors:  Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2019-02-01       Impact factor: 5.923

Review 7.  SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.

Authors:  Elisabetta Valentini; Marta Di Martile; Donatella Del Bufalo; Simona D'Aguanno
Journal:  J Exp Clin Cancer Res       Date:  2021-04-15

8.  Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis.

Authors:  Roli M Misra; Manmohan S Bajaj; Vaijayanti P Kale
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 9.  Established and Emerging Biomarkers in Cutaneous Malignant Melanoma.

Authors:  Stamatina Verykiou; Robert A Ellis; Penny E Lovat
Journal:  Healthcare (Basel)       Date:  2014-01-14

10.  Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts.

Authors:  Ruixia Huang; Lise Mari K Andersen; Einar K Rofstad
Journal:  J Transl Med       Date:  2017-10-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.